MONTREAL, October 2, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented an updated, comprehensive technology overview of its nucleic acid polymer (NAP) technology at the Inaugural “Targeting HBV Symposium” at the 2017 Discovery on Target Meeting Held from September 25-29th in Boston , USA (http://www.discoveryontarget.com/Targeting-HBV/).
Replicor’s presentation gathered together all of the latest data on NAPs including:
This presentation can be downloaded at www.replicor.com/science/conference-presentations.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.